CAH logo

CAH
Cardinal Health, Inc.

3,438
Mkt Cap
$46.98B
Volume
378,716.00
52W High
$233.60
52W Low
$137.75
PE Ratio
30.68
CAH Fundamentals
Price
$200.53
Prev Close
$200.61
Open
$201.73
50D MA
$204.78
Beta
0.28
Avg. Volume
1.65M
EPS (Annual)
$6.45
P/B
-16.65
Rev/Employee
$3.86M
$46,274.00
Loading...
Loading...
News
all
press releases
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks.
News Placeholder
More News
News Placeholder
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
News Placeholder
Is CAH Becoming the Backbone of US Healthcare Infrastructure?
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.
News Placeholder
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
News Placeholder
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.
News Placeholder
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
News Placeholder
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q4 results, though data security threats remain a key risk.
News Placeholder
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
Cardinal Health's Pharmaceutical & Specialty segment posts strong Q3 growth, but can specialty momentum continue powering earnings?
News Placeholder
Rigetti Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
RGTI beats Q1 estimates as revenue nearly triples, gross margin expands and adoption grows for its quantum systems and cloud platforms.
News Placeholder
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available